Cocaine-Related Disorders Clinical Trial
Official title:
Acoustic Startle Reduction In Cocaine Dependence
Verified date | August 2019 |
Source | Emory University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Chronic cocaine administration leads to changes in brain function that persist long after the
acute withdrawal phase. The acoustic startle response (ASR) is a well characterized reflexive
response to a sudden acoustic stimulus. The ASR is mediated by a simple 3-synapse subcortical
circuit; it is modulated in part by brain areas and neurotransmitters associated with cocaine
administration. Our initial study and subsequent replication reveals a profound diminution of
the ASR in cocaine-dependent subjects after a brief period of abstinence. Our preliminary
findings indicate that first degree relatives of cocaine-dependent subjects also have reduced
startle compared to healthy controls. The findings of low ASR in rats and humans during
cocaine washout and low ASR in family members suggests there may be both a trait and state
component of the startle reductions we have reported.
The central objectives of this proposal are to dissect this finding with regard to its
development and persistence in early and later phases of cocaine abstinence in humans; to
ascertain whether startle reduction and its potential normalization during later abstinence
is a predictor of clinical course in human subjects with cocaine dependence; and to examine
whether startle reduction is, at least in part, a vulnerability trait for the development of
cocaine dependence. This latter Aim will be carried out in humans by testing siblings of
cocaine-dependent subjects.
Cocaine dependence is an enormous public health problem. The significance of this work lies
in the potential for the ASR reduction to serve as a reliable, easily repeatable biological
measure of cocaine-induced brain changes that may enhance outcome prediction so that tailored
treatments may be directed at those patients most vulnerable to relapse, given the
restriction of resources for available for substance abuse treatment.
Status | Completed |
Enrollment | 144 |
Est. completion date | July 19, 2011 |
Est. primary completion date | July 19, 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria: Cocaine dependent subjects: 1. males or females, 2. age 18-80, 3. with a DSM-IV diagnosis of cocaine dependence, 4. a usage history characterized by a minimum of 1 year of at least $50 per day or weekly binges of at least $200 of cocaine use. Exclusion Criteria: 1. current clinically significant medical illness (including HIV, because of possible confound of neurological involvement), 2. current or past neurological illness, and no history of head trauma with loss of consciousness = 5 minutes because of the possible confound of neurological damage to startle-modulating brain areas, 3. other Axis I psychiatric disorder currently or in the previous three months with the exception of substance induced disorders as determined by SCID, 4. history of schizophrenia, schizoaffective disorder, posttraumatic stress disorder, or bipolar disorder, 5. known hearing impairments (intact hearing will be insured by brief audiology screening), 6. dependence on other drugs or alcohol within the previous 6 months, as confirmed by ASI. Healthy controls: 1. males or females, 2. age 18-80. Exclusion criteria: 1. history of any Axis I psychiatric illness or history of treatment as determined by SCID Axis I, 2. substance dependence or abuse history by ASI and SCID, 3. no current clinically significant medical illness (including HIV), 4. current or past neurological illness, or history of head trauma with loss of consciousness = 5 minutes because of the possible confound of neurological damage to startle-modulating brain areas, 5. known hearing impairments (intact hearing will be insured by brief audiology screening), 6. Axis I disorder, including substance dependence, in first degree family member. Family members of cocaine subjects: 1. males or females, 2. age 18-80, 3. family member of cocaine-dependent subject enrolled in study. Exclusion criteria: 1. history of any Axis I psychiatric illness or history of treatment as determined by SCID Axis I, 2. substance dependence history by ASI and SCID, or substance abuse within the prior 5 years, 3. no current clinically significant medical illness (including HIV), 4. current or past neurological illness, or history of head trauma with loss of consciousness, 5. known hearing impairments |
Country | Name | City | State |
---|---|---|---|
United States | Atlanta Veterans Adminstration Medical Center | Decatur | Georgia |
Lead Sponsor | Collaborator |
---|---|
Emory University | National Institute on Drug Abuse (NIDA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acoustic startle magnitude | Magnitude of acoustic startle response as measured by electromyography of eyeblink. | at baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01526538 -
Improving Learning-based Treatment of Cocaine Dependence With Medication
|
Phase 2 | |
Completed |
NCT00877435 -
Prize Reinforcement Contingency Management for Cocaine Dependence: a 24-week Randomized Controlled Trial
|
N/A | |
Completed |
NCT00217997 -
Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals
|
N/A | |
Active, not recruiting |
NCT00094315 -
Development of Human Laboratory Study Model of Cocaine Relapse Prevention II - 1
|
Phase 1 | |
Terminated |
NCT00142883 -
The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3
|
N/A | |
Completed |
NCT00218348 -
Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo
|
Phase 2 | |
Completed |
NCT00158132 -
Effectiveness of Amantadine and Propranolol for Treating Cocaine Dependence - 2
|
Phase 2 | |
Completed |
NCT00142844 -
Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1
|
Phase 2 | |
Completed |
NCT00015054 -
Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3
|
Phase 2 | |
Completed |
NCT00000294 -
Effects of Carvedilol on Cocaine Use in Humans - 11
|
Phase 2 | |
Completed |
NCT00000308 -
Dextroamphetamine-Cocaine Behavioral Intervention - 5
|
Phase 2 | |
Completed |
NCT00000314 -
M-CPP and Fenfluramine in Cocaine Addicts - 3
|
Phase 2 | |
Completed |
NCT00000277 -
Mazindol for Cocaine Abuse - 2
|
Phase 2 | |
Completed |
NCT00000188 -
Selegiline in Treatment of Cocaine Dependence - 2
|
Phase 2 | |
Completed |
NCT00000280 -
Glutaminergic Agents for Cocaine Abuse - 5
|
Phase 1 | |
Completed |
NCT00000282 -
Pemoline for Cocaine Abuse - 7
|
Phase 2 | |
Completed |
NCT00000278 -
Disulfiram for Cocaine-Alcohol Abuse - 3
|
Phase 2 | |
Completed |
NCT00000306 -
Dextroamphetamine as Adjunct in Cocaine/Opiate Dependent Patients - 3
|
Phase 2 | |
Completed |
NCT00000281 -
Pharmacotherapy for Schizophrenic Drug Users - 6
|
Phase 2 | |
Terminated |
NCT00000276 -
Dopamine Reuptake Inhibitors of Cocaine Abuse - 1
|
Phase 1 |